Startseite>>Signaling Pathways>> Tyrosine Kinase>>Avitinib

Avitinib (Synonyms: AC0010)

Katalog-Nr.GC42884

Avitinib (AC0010) ist ein irreversibler, mutantenselektiver EGFR-Inhibitor, der EGFR-T790M-Resistenzmutationen bei nicht-kleinzelligem Lungenkrebs (NSCLC) wirksam hemmt. Abivertinib ist ebenfalls ein neuartiger BTK-Hemmer.

Products are for research use only. Not for human use. We do not sell to patients.

Avitinib Chemische Struktur

Cas No.: 1557267-42-1

Größe Preis Lagerbestand Menge
1mg
49,00 $
Auf Lager
5mg
63,00 $
Auf Lager
10mg
111,00 $
Auf Lager
25mg
204,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents Related Products

Avitinib is a pyrrolopyrimidine-based, irreversible inhibitor of the epidermal growth factor receptor (EGFR). It is selective for EGFR-active and T790M mutations, exhibiting a 298-fold increase in potency compared with wild-type EGFR. In a xenograft model, oral administration of 500 mg/kg avitinib was shown to result in complete remission of tumors with EGFR-active and T790M mutations.

Bewertungen

Review for Avitinib

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Avitinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.